Search results
Showing 1591 to 1605 of 7959 results
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)
Evidence-based recommendations on somapacitan (Sogroya) for treating growth hormone deficiency in people 3 to 17 years.
Evidence-based recommendation on linzagolix (Yselty) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.